NEW YORK, April 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma
Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma
A patient specific case scenario on advanced lung cancer in a situation involving a patient with EGFR Mutation Positive Adenocarcinoma that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progression reveals:
• Decisions in treatment and tests through disease stages
• Factors influencing their decisions
• Barriers to optimal patient care
• Confidence in treatment
Data has been synthesized to show all responses and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on Advanced Lung Cancer.
Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists' choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.
This report allows you to:
• Understand what occurs with actual patients
• Access the most up-to-date prescribing trends
• Gain actionable data for developing and improving your market strategies
• Pinpoint needs of your target audience
• Focus resources to maximize the effectiveness of your budget
• Understand where your product fits
• Understand where your competitor's product fits
• Design messages to advance brand performance
Table of Contents
Executive Summary - US Oncologist Survey5
Optimizing Treatment of Advanced Lung Cancer:5
Chapter 1: Introduction6
Table 1: Treatment Options in Advanced Lung Cancer6
Chapter 2: Respondent Demographics8
Table 2: Eligibility Criteria for Survey Participation8
Figure 2.1 Gender of Survey Respondents8
Figure 2.2 Years Since Medical School Graduation9
Figure 2.3 Practice Settings9
Figure 2.4 Practices in NCI Cancer Centers10
Figure 2.5 Geographic Settings10
Figure 2.6 Survey Respondents by State's Lung Cancer Mortality11
Figure 2.7 Number of Physicians in Practice Groups12
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen12
Chapter 3: Treatment of an EGFR Mutation Positive Adenocarcinoma13
Figure 3.1 First line chemotherapy regimen13
Figure 3.2 Factors influencing treatment decision14
Figure 3.3 Confidence in treating patient to an optimal outcome16
Figure 3.4 Sequence of treatment choices17
Figure 3.5 Factors influencing treatment decision18
Figure 3.6 Barriers to management of advanced lung cancer20
Chapter 4: Summary23
Appendix A: Survey Instrument24
Companies mentioned
Eli Lilly, Genentech/Roche, Bristol-Myers Squibb, Glaxo Smith Kline, Pfizer, Sanofi-aventis
To order this report:
: Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker